- Main
Genetically adjusted PSA levels for prostate cancer screening
- Kachuri, Linda;
- Hoffmann, Thomas J;
- Jiang, Yu;
- Berndt, Sonja I;
- Shelley, John P;
- Schaffer, Kerry R;
- Machiela, Mitchell J;
- Freedman, Neal D;
- Huang, Wen-Yi;
- Li, Shengchao A;
- Easterlin, Ryder;
- Goodman, Phyllis J;
- Till, Cathee;
- Thompson, Ian;
- Lilja, Hans;
- Van Den Eeden, Stephen K;
- Chanock, Stephen J;
- Haiman, Christopher A;
- Conti, David V;
- Klein, Robert J;
- Mosley, Jonathan D;
- Graff, Rebecca E;
- Witte, John S
Published Web Location
https://doi.org/10.1038/s41591-023-02277-9Abstract
Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer-related PSA variation has potential to improve screening utility. In this study, we discovered 128 genome-wide significant associations (P < 5 × 10−8) in a multi-ancestry meta-analysis of 95,768 men and developed a PSA polygenic score (PGSPSA) that explains 9.61% of constitutive PSA variation. We found that, in men of European ancestry, using PGS-adjusted PSA would avoid up to 31% of negative prostate biopsies but also result in 12% fewer biopsies in patients with prostate cancer, mostly with Gleason score <7 tumors. Genetically adjusted PSA was more predictive of aggressive prostate cancer (odds ratio (OR) = 3.44, P = 6.2 × 10−14, area under the curve (AUC) = 0.755) than unadjusted PSA (OR = 3.31, P = 1.1 × 10−12, AUC = 0.738) in 106 cases and 23,667 controls. Compared to a prostate cancer PGS alone (AUC = 0.712), including genetically adjusted PSA improved detection of aggressive disease (AUC = 0.786, P = 7.2 × 10−4). Our findings highlight the potential utility of incorporating PGS for personalized biomarkers in prostate cancer screening.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.